Hikma Pharma's profits down 2.2%, points to Middle East unrest

15 March 2012

The London-listed group, Hikma Pharma reported an adjusted profit attributable to shareholders of $100.9m last year, down 2.2% due to political unrest in some of its main markets in the Middle East and North Africa, Ahram has reported. Hikma, which sells branded drugs and also has an injectable drugs business in the United States and a generics division, has announced that its adjusted earnings per share dropped 2.6% to 51%.

A MEED Subscription...

Subscribe or upgrade your current MEED.com package to support your strategic planning with the MENA region’s best source of business information. Proceed to our online shop below to find out more about the features in each package.

Get Notifications